Literature DB >> 18336938

Analysis of reproducibility of respiration-triggered gated radiotherapy for lung tumors.

Femke O B Spoelstra1, John R van Sörnsen de Koste, Johan P Cuijpers, Frank J Lagerwaard, Ben J Slotman, Suresh Senan.   

Abstract

PURPOSE: Respiration-gated radiotherapy (RGRT) can decrease the toxicity of chemo-radiotherapy (CT-RT) by allowing use of smaller treatment fields. RGRT requires a predictable relationship between tumor position and external surrogate, which must be verified during treatment. Time-integrated electronic portal imaging (TI-EPI) identifies mean intra-fractional positions of moving structures, and was used to study reproducibility of anatomy during RGRT for lung tumors.
MATERIALS AND METHODS: TI-EPIs were acquired using an amorphous silicon-based electronic portal imaging system (EPID, aS500) in continuous image acquisition mode in 11 patients treated with audio-coached RGRT at end-inspiration. The Varian Real-time Position Management (RPM) system was used for 4DCT imaging and RGRT delivery. All TI-EPI portals were co-registered to corresponding digitally reconstructed radiographs (DRR) of the planning 4DCT using the spinal column. Displacements in tumor position or that of an adjacent bronchus during RGRT was measured relative to the reference structure on the DRR.
RESULTS: Vertebra-matched portals revealed systematic (Sigma) and random (sigma) errors of 1.8 and 1.3mm in medial-lateral direction and 1.7 and 1.7 mm in cranial-caudal direction, indicating a reproducible tumor/bronchus position during the RPM-triggered gates.
CONCLUSIONS: RGRT delivery at end-inspiration can achieve reproducible internal anatomy in 'gated' fields delivered with audio-coaching.

Entities:  

Mesh:

Year:  2008        PMID: 18336938     DOI: 10.1016/j.radonc.2008.02.008

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  7 in total

1.  Potential for adaptive dose escalation in radiotherapy for patients with locally advanced non-small-cell lung cancer in a low mid income setting.

Authors:  Sushma Agrawal; Sunil Kumar; Anil K Maurya
Journal:  Br J Radiol       Date:  2017-01-03       Impact factor: 3.039

2.  Radiotherapy for a second primary lung cancer arising post-pneumonectomy: planning considerations and clinical outcomes.

Authors:  Sashendra Senthi; Cornelis J A Haasbeek; Frank J Lagerwaard; Wilko F Verbakel; Patricia F de Haan; Ben J Slotman; Suresh Senan
Journal:  J Thorac Dis       Date:  2013-04       Impact factor: 2.895

3.  Synchronous monitoring of external/internal respiratory motion: validity of respiration-gated radiotherapy for liver tumors.

Authors:  Takeshi Nishioka; Seiko Nishioka; Masaki Kawahara; Shigeru Tanaka; Hiroki Shirato; Ken Nishi; Tadao Hiromura
Journal:  Jpn J Radiol       Date:  2009-08-28       Impact factor: 2.374

4.  Fluoroscopy as a surrogate for lung tumour motion.

Authors:  H A McNair; A Kavanagh; C Powell; J R N Symonds-Tayler; M Brada; P M Evans
Journal:  Br J Radiol       Date:  2011-08-09       Impact factor: 3.039

5.  Respiratory gating during stereotactic body radiotherapy for lung cancer reduces tumor position variability.

Authors:  Tetsuo Saito; Tomohiko Matsuyama; Ryo Toya; Yoshiyuki Fukugawa; Takamasa Toyofuku; Akiko Semba; Natsuo Oya
Journal:  PLoS One       Date:  2014-11-07       Impact factor: 3.240

6.  Analysis of the optimum internal margin for respiratory-gated radiotherapy using end-expiratory phase assessments using a motion phantom.

Authors:  Yuji Yaegashi; Kunihiko Tateoka; Takuya Nakazawa; Kazunori Fujimoto; Katsumi Shima; Junji Suzuki; Akihiro Nakata; Yuichi Saito; Tadanori Abe; Koichi Sakata; Masato Hareyama
Journal:  J Appl Clin Med Phys       Date:  2012-03-08       Impact factor: 2.102

7.  Dosimetric comparison of dose accumulation between rigid registration and deformation registration in intensity-modulated radiation therapy for large volume non-small cell lung cancer.

Authors:  Jianxin Ren; Guanzhong Gong; Xinsen Yao; Yong Yin
Journal:  Transl Cancer Res       Date:  2019-12       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.